Developing supercharged T cell therapies
We are focused on T cell receptor engineered T cell therapies, TCR-Ts, a promising modality that holds the potential to generate transformational responses in patients with solid tumors. By armoring T cells with the most advanced enhancements in a single T cell, T-knife is designing T cell therapies to achieve a clinically meaningful impact for patients.
Discovering novel, high affinity and high specificity, human TCRs targeting the most immunogenic epitopes
Engineering T cells with tailored, best-in-class enhancements to create supercharged TCR-Ts
Building a pipeline of TCR-Ts designed to improve response rates and durability in solid tumor cancers
Advancing portfolio of TCR therapies for solid tumors
Through the use of natural, fully human TCRs and tailored armoring, T-knife’s product candidates are designed to induce an organically optimized immune signaling cascade intended to stimulate a potent T cell-driven immune response. Our TCR therapies target tumor antigens in multiple, difficult to treat solid tumor indications.
TK-6302 is T-knife’s lead TCR-T and targets PRAME, an antigen expressed in a number of solid tumors. As shown in a complex 3-dimensional (3D) spheroid tumor model, TK-6302 destroys multiple rounds of tumors, while control T cells are ineffective.